TransCode Therapeutics Announces Article Published in the Journal Cancers Detailing the Potential for Short RNA-based Drugs in Cancer and a Broad Range of Disorders

Excerpt from the Press Release:

BOSTON, March 23, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, in collaboration with teams from, Massachusetts General Hospital, Michigan State University and Northeastern University, published an article in the journal Cancers titled, Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine. The article was published on March 21, 2022.

The article describes the development, challenges, and clinical successes of short RNA-based drugs and details several examples of how these RNA drugs are designed, chemically modified, and delivered for treatment of cancer, cardiovascular disease, and rare genetic disorders. In addition, the article highlights key similarities and differences between various short non-coding RNA platforms and discusses considerations to maximize treatment efficacy of RNA-based therapeutics. TransCode Co-Founder and scientific advisor, Dr. Anna Moore, was a contributing author to the article.

“The field of RNA therapeutics has matured to the point of clinical translation and is poised to transform the way we treat disease over the next decade,” commented Dr. Zdravka Medarova, Co-Founder and Chief Technology Officer of TransCode. “This report provides a snapshot of the field of RNA therapeutics and outlines the future for short non-coding RNAs as a therapeutic platform for a broad range of disorders, including cancer.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release